(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
28 October 2021 (28.10.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/214469 A1

(51) International Patent Classification:
C07D 403/14 (2006.01) *A61P 17/00* (2006.01)
A61K 31/506 (2006.01) *A61P 17/04* (2006.01)
A61P 1/04 (2006.01) *A61P 29/00* (2006.01)
A61P 11/06 (2006.01)

(21) International Application Number:
PCT/GB2021/050971

(22) International Filing Date:
22 April 2021 (22.04.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2005858.2 22 April 2020 (22.04.2020) GB

(71) Applicant: **HEPTARES THERAPEUTICS LIMITED** [GB/GB]; Granta Park, Great Abington, Cambridge Cambridgeshire CB21 6DG (GB).

(72) Inventors: **CONGREVE, Miles Stuart**; c/o Heptares Therapeutics Limited, Granta Park, Great Abington, Cambridge Cambridgeshire CB21 6DG (GB). **FIELDHOUSE, Charlotte**; c/o Heptares Therapeutics Limited, Granta Park, Great Abington, Cambridge Cambridgeshire CB21 6DG (GB). **SWAIN, Nigel Alan**; c/o Heptares Therapeutics Limited, Granta Park, Great Abington, Cambridge Cambridgeshire CB21 6DG (GB). **PICKWORTH, Mark**; c/o Heptares Therapeutics Limited, Granta Park, Great Abington, Cambridge Cambridgeshire CB21 6DG (GB). **HANNAH, Duncan Robert**; c/o Heptares Therapeutics Limited, Granta Park, Great Abington, Cambridge Cambridgeshire CB21 6DG (GB).

(74) Agent: **STRATAGEM INTELLECTUAL PROPERTY MANAGEMENT LIMITED**; Meridian Court, Comberton Road, Toft, Cambridge Cambridgeshire CB23 2RY (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

WO 2021/214469 A1

(54) Title: H4 ANTAGONIST COMPOUNDS

(57) Abstract: The disclosure herein relates to azetidinylpyrimidin-2-amine derivatives, their use as Histamine H4 receptor antagonists and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with H4 receptors.